Microbot Medical (MBOT) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nephros (NEPH) has outperformed Microbot Medical (MBOT) over the past year, losing 46.4% versus a loss of 62.8%. Over five years, NEPH leads with a -63.6% price change compared with -87.4% for MBOT. Microbot Medical is the larger company by market cap ($45.7 million vs $28.4 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBOT | NEPH |
|---|---|---|
| Share price | $0.68 | $2.61 |
| Market cap | $45.67M | $28.37M |
| 1-day change | -8.52% | -8.10% |
| YTD return | -66.00% | -46.52% |
| 1-year return | -62.84% | -46.41% |
| 5-year return | -87.43% | -63.60% |
| P/E ratio (TTM) | — | 15.35 |
| Forward P/E | — | 11.86 |
| EPS (TTM) | $-0.27 | $0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $18.79M |
| Revenue growth (YoY) | — | +32.67% |
| Net income (latest FY) | $-13.14M | $1.19M |
| Gross margin | — | 61.87% |
| Operating margin | — | 6.10% |
| Net margin | — | 6.35% |
| 52-week high | $2.86 | $6.42 |
| 52-week low | $0.52 | $2.61 |
| Distance from 52-week high | -76.22% | -59.35% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +830.88% | +139.46% |
| Average volume | 922.53K | 48.33K |
| Shares outstanding | 67.16M | 10.87M |
| Employees | 43 | 36 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEPH has outperformed MBOT by 16.4 percentage points over the past year.
About Microbot Medical
MBOT stock →Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
Health Care · Medical/Dental Instruments · 43 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
MBOT vs NEPH FAQ
Which is bigger, Microbot Medical or Nephros?
Microbot Medical (MBOT) is larger, with a market capitalization of $45.67M compared with $28.37M for Nephros (NEPH).
Which stock has performed better over the past year, MBOT or NEPH?
NEPH returned -46.41% over the past 12 months, compared with -62.84% for MBOT (price return, excluding dividends). Past performance does not predict future results.
Are Microbot Medical and Nephros in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.